KR101014097B1 - 대장의 건강 증진 효능을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 - Google Patents
대장의 건강 증진 효능을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 Download PDFInfo
- Publication number
- KR101014097B1 KR101014097B1 KR1020080057422A KR20080057422A KR101014097B1 KR 101014097 B1 KR101014097 B1 KR 101014097B1 KR 1020080057422 A KR1020080057422 A KR 1020080057422A KR 20080057422 A KR20080057422 A KR 20080057422A KR 101014097 B1 KR101014097 B1 KR 101014097B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactobacillus
- health
- active ingredient
- large intestine
- promoting
- Prior art date
Links
- 241000186610 Lactobacillus sp. Species 0.000 title claims abstract description 183
- 230000036541 health Effects 0.000 title claims abstract description 29
- 230000001737 promoting effect Effects 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title description 7
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 claims abstract description 46
- 241000193468 Clostridium perfringens Species 0.000 claims abstract description 36
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- 206010061218 Inflammation Diseases 0.000 claims abstract description 20
- 230000004054 inflammatory process Effects 0.000 claims abstract description 20
- 102000004127 Cytokines Human genes 0.000 claims abstract description 15
- 108090000695 Cytokines Proteins 0.000 claims abstract description 15
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 14
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 13
- 210000004877 mucosa Anatomy 0.000 claims abstract description 13
- 230000000112 colonic effect Effects 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 230000028327 secretion Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 241000606215 Bacteroides vulgatus Species 0.000 claims abstract description 8
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 claims abstract description 4
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 23
- 229940035901 lactobacillus sp Drugs 0.000 claims description 17
- 210000002429 large intestine Anatomy 0.000 claims description 17
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 210000001072 colon Anatomy 0.000 claims description 10
- 230000002790 anti-mutagenic effect Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 241000509622 Mitsuokella multacida Species 0.000 claims description 3
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims 2
- 230000008821 health effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 32
- 230000005764 inhibitory process Effects 0.000 abstract description 31
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract description 20
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract description 18
- 230000003505 mutagenic effect Effects 0.000 abstract description 16
- 206010009887 colitis Diseases 0.000 abstract description 15
- 239000003471 mutagenic agent Substances 0.000 abstract description 15
- 231100000707 mutagenic chemical Toxicity 0.000 abstract description 15
- 235000019985 fermented beverage Nutrition 0.000 abstract description 6
- 230000006698 induction Effects 0.000 abstract description 5
- 230000002072 anti-mutant effect Effects 0.000 abstract description 2
- 230000000369 enteropathogenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 61
- 241000606125 Bacteroides Species 0.000 description 50
- 241000894006 Bacteria Species 0.000 description 38
- 240000006024 Lactobacillus plantarum Species 0.000 description 32
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 32
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 32
- 229940072205 lactobacillus plantarum Drugs 0.000 description 32
- 239000002609 medium Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 22
- 239000007788 liquid Substances 0.000 description 20
- 238000012986 modification Methods 0.000 description 17
- 239000004310 lactic acid Substances 0.000 description 16
- 235000014655 lactic acid Nutrition 0.000 description 16
- 230000004048 modification Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000872 buffer Substances 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 13
- 241000186660 Lactobacillus Species 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229940039696 lactobacillus Drugs 0.000 description 10
- 239000008176 lyophilized powder Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 239000006188 syrup Substances 0.000 description 8
- 235000020357 syrup Nutrition 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 230000002019 anti-mutation Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 241000186605 Lactobacillus paracasei Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000006152 selective media Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000012288 TUNEL assay Methods 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229920002567 Chondroitin Polymers 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 240000002605 Lactobacillus helveticus Species 0.000 description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 231100000357 carcinogen Toxicity 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 230000001738 genotoxic effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 210000004922 colonic epithelial cell Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000021022 fresh fruits Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 235000021579 juice concentrates Nutrition 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 208000014081 polyp of colon Diseases 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical compound C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 1
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000605114 Pedobacter heparinus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000323021 Thiacidas Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021096 adenomatous colon polyp Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940019765 dermatin Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000021274 meat intake Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical class ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- ZDHURYWHEBEGHO-UHFFFAOYSA-N potassiopotassium Chemical compound [K].[K] ZDHURYWHEBEGHO-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940074386 skatole Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (16)
- 대장의 건강 증진 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801(기탁번호:KCTC 11315BP).
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 돌연변이원 4-NQO(4-nitroquinoline-1-oxide)에 대한 항돌연변이능을 갖는 것을 특징으로 하는 대장의 건강 증진 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 클로스트리디움 퍼프린젠스(Clostridium perfringens)의 활성을 억제하는 것을 특징으로 하는 대장의 건강 증진 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 박테로이데스 불가투스(Bacteroides vulgatus)의 활성을 억제하는 것을 특징으로 하는 대장의 건강 증 진 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 박테로이드 물티아시더스(Bacteroides multiacidus)의 활성을 억제하는 것을 특징으로 하는 대장의 건강 증진 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 대장 점막의 염증 유발과 연관된 콘드로이티나제(chondroitinase)활성을 억제하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 전염증성 사이토카인 분비와 연관된 TLR4(Toll Like Receptor 4)의 활성을 억제하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항에 있어서,상기 락토바실러스(Lactobacillus) sp. HY7801은 항염즘성 사이토카인 IL-10을 증가시키는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 락토바실러스(Lactobacillus) sp. HY7801.
- 제1항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 염증 예방 및 치료용 약학조성물.
- 제2항 내지 제8항 중 어느 한 항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 염증 예방 및 치료용 약학 조성물.
- 제1항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 발효유.
- 제2항 내지 제8항 중 어느 한 항의 락토바실러스(Lactobacillus) sp. HY7801을 유 효성분으로 함유하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 발효유.
- 제1항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 음료.
- 제2항 내지 제8항 중 어느 한 항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 음료.
- 제1항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 건강기능식품.
- 제2항 내지 제8항 중 어느 한 항의 락토바실러스(Lactobacillus) sp. HY7801을 유효성분으로 함유하는 것을 특징으로 하는 대장의 건강 증진에 효능을 갖는 건강기능식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080057422A KR101014097B1 (ko) | 2008-06-18 | 2008-06-18 | 대장의 건강 증진 효능을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080057422A KR101014097B1 (ko) | 2008-06-18 | 2008-06-18 | 대장의 건강 증진 효능을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090131510A KR20090131510A (ko) | 2009-12-29 |
KR101014097B1 true KR101014097B1 (ko) | 2011-02-14 |
Family
ID=41690710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080057422A KR101014097B1 (ko) | 2008-06-18 | 2008-06-18 | 대장의 건강 증진 효능을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101014097B1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101239806B1 (ko) * | 2011-04-01 | 2013-03-06 | 주식회사한국야쿠르트 | 면역증강 활성을 가지는 신규한 락토바실러스 플란타룸 에이취와이 7712 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100611720B1 (ko) * | 2004-02-10 | 2006-08-11 | 매일유업주식회사 | 비피도박테리움 인팬티스 Maeil-K9 유래의 세포성분함유 추출물 및 이를 함유하는 위암 및 대장암의 예방용및 치료용 조성물 |
KR100813637B1 (ko) * | 2002-09-16 | 2008-03-14 | 매일유업주식회사 | 비피도박테리움 인팬티스 maeil-k9 유래의펩티도글리칸 함유 추출물 및 이를 함유하는 로타바이러스감염성 설사증의 예방용 및 치료용 조성물 |
-
2008
- 2008-06-18 KR KR1020080057422A patent/KR101014097B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100813637B1 (ko) * | 2002-09-16 | 2008-03-14 | 매일유업주식회사 | 비피도박테리움 인팬티스 maeil-k9 유래의펩티도글리칸 함유 추출물 및 이를 함유하는 로타바이러스감염성 설사증의 예방용 및 치료용 조성물 |
KR100611720B1 (ko) * | 2004-02-10 | 2006-08-11 | 매일유업주식회사 | 비피도박테리움 인팬티스 Maeil-K9 유래의 세포성분함유 추출물 및 이를 함유하는 위암 및 대장암의 예방용및 치료용 조성물 |
Non-Patent Citations (2)
Title |
---|
논문 1: Korean J. Food Preservation |
논문 2: Curr. Microbiol. |
Also Published As
Publication number | Publication date |
---|---|
KR20090131510A (ko) | 2009-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101017448B1 (ko) | 대장의 건강 증진 효능을 갖는 비피도박테리움 롱검 에이취와이8004 및 이를 유효성분으로 함유하는 제품 | |
EP1005353B1 (en) | Pharmaceutical preparation comprising lactobacillus casei rhamnosus | |
KR101255050B1 (ko) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 | |
KR101075557B1 (ko) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 | |
KR101098241B1 (ko) | 요로감염과 칸디다성 질염을 억제하는 활성을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 | |
KR102063757B1 (ko) | 가드네렐라 바기날리스 및 칸디다 알비칸스에 항균 효과를 갖는 질염 치료 또는 개선용 유산균 | |
KR100996056B1 (ko) | 대장염 발생 예방 효능을 가진 락토바실러스 브레비스에이치와이7401 및 이를 유효성분으로 함유하는 제품 | |
KR20180044245A (ko) | 변비 개선 효능을 갖는 신규한 유산균 및 이의 용도 | |
KR101656208B1 (ko) | 염증 질환 예방 또는 치료용 조성물 | |
KR102294445B1 (ko) | 영유아 유래 유산균 락토바실러스 파라카제이 mg4592 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 | |
KR20190111582A (ko) | 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 파라카제이 균주 | |
AU2020101490A4 (en) | Lactobacillus fermentum strain v3 and its efficacies of intestinal microflora regulation, anti-inflammation and cancer prevention | |
KR101075558B1 (ko) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 | |
KR20180011490A (ko) | 프로바이오틱 활성을 갖는 신규 락토바실러스 퍼멘텀 및 이의 용도 | |
KR102294437B1 (ko) | 영유아 유래 유산균 락토바실러스 플란타럼 mg4553 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 | |
KR102294442B1 (ko) | 영유아 유래 유산균 락토바실러스 플란타럼 mg4555 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 | |
US10098916B2 (en) | Strains of the genus Lactobacillus and use thereof | |
KR20190111584A (ko) | 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 퍼멘툼 균주 | |
KR101014097B1 (ko) | 대장의 건강 증진 효능을 갖는 락토바실러스 에스피. 에이취와이 7801 및 이를 유효성분으로 함유하는 제품 | |
KR102668292B1 (ko) | 신규한 락토바실러스 퍼멘텀 atg-v5 균주 또는 이를 포함하는 면역증강용 조성물 | |
KR102294456B1 (ko) | 영유아 유래 유산균 락토바실러스 람노서스 mg4502 및 이를 포함하는 장 건강 증진, 항산화 및 항비만용 조성물 | |
KR20190048732A (ko) | 염증의 예방 및 치료 효과를 갖는 락토바실러스 존소니 아이디씨씨 9203 및 이의 용도 | |
TWI727378B (zh) | 嗜熱鏈球菌菌株st4及其抗發炎及預防癌症功效 | |
KR20180040899A (ko) | 신규한 락토바실러스 플란타룸 Ln4 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물 | |
KR20180040894A (ko) | 신규한 락토바실러스 플란타룸 Lb41 균주 및 이를 포함하는 비만의 예방 및 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140203 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150202 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160202 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170202 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180202 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190207 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200204 Year of fee payment: 10 |